Skip to main content
OpenTrials
Completed

NCT Number: NCT06141512

Improvements in Aerobic Fitness With Exercise Training: the Role of Myokines

For both healthy adults and patients with cardiovascular disease (CVD), aerobic fitness (V̇O2max) is a stronger predictor of the risk of future chronic disease and premature death than other established risk factors such as hypertension, smoking, or Type 2 diabetes. It is important to improve the understanding of the regulation of V̇O2max to enable optimisation of interventions aimed at increasing V̇O2max in the current predominantly sedentary population. Currently, only exercise training is a viable method for increasing V̇O2max. However, ~10-20% of people who follow fully supervised, standardised training interventions do not demonstrate a measurable increase in V̇O2max. Low response to training is a clinically relevant concern, but the large variability in response to exercise training also provides an opportunity to dissect out the molecular mechanisms responsible for adaptations to V̇O2max by contrasting low vs. high responders to training. It has been previously demonstrated that low responders for VO2max fail to up regulate a number of genes that encode putative 'myokines', while the high responders demonstrated a significant increase in the expression of these genes, suggesting these myokines may play an important mechanistic role in modulating VO2max. The aim of the present study is to examine whether low responders for VO2max have an attenuated increase in the plasma levels of the previously identified myokines.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Stirling

Stirling, FK9 4LA, United Kingdom

About this study

For both healthy adults and patients with cardiovascular disease (CVD), aerobic fitness (V̇O2max) is a stronger predictor of the risk of future chronic disease and premature death than other established risk factors such as hypertension, smoking, or Type 2 diabetes. Considering the large medical and economic burden of physical inactivity-related chronic disease it is important to improve the understanding of the regulation of V̇O2max to enable optimisation of interventions aimed at increasing V̇O2max in the current predominantly sedentary population. Furthermore, there is a need to identify novel drug targets to aid pharmacological intervention in those individuals who are unwilling or unable to improve V̇O2max through exercise.

Currently, only exercise training is a viable method for increasing V̇O2max. However, although exercise training on average improves V̇O2max, ~10-20% of people who follow fully supervised, standardised training interventions do not demonstrate a measurable increase in V̇O2max. Low response to training is a clinically relevant concern, but the large variability in response to exercise training also provides an opportunity to dissect out the molecular mechanisms responsible for adaptations to V̇O2max by contrasting low vs. high responders to training.

Using this approach it has previously been shown that in skeletal muscle samples obtained pre- and post- training, 86 genes are differentially regulated in high compared to low responders for V̇O2max. Strikingly, out of these 86 genes, 13 genes encode proteins that have been reported to be released by muscle during or after exercise (i.e., 'messenger proteins' termed myokines). This strongly suggests low responders to exercise training fail to sufficiently upregulate the production and release of these myokines, and that this is (at least partly) the reason why these people do not manage to improve their V̇O2max as much as high responders. However, in order to confirm a mechanistic role of these myokines in increasing V̇O2max, it needs to be demonstrated that beside the change in gene expression, the change in the plasma levels of these myokines is also impaired in low responders for V̇O2max.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male
  • Age ≥ 18 y or <40 y
  • BMI < 35 kg/m2
  • otherwise healthy, untrained individuals

Exclusion criteria

  • Age <18 y or >40 y
  • BMI > 35 kg/m2
  • classification of 'highly physically active' according to the International Physical Activity Questionnaire (IPAQ)
  • answering 'yes' to one or more questions on a standard Physical Activity Readiness Questionnaire (PAR-Q)
  • resting heart rate ≥100bpm, clinically significant hypertension (140/90 mmHg)
  • a personal history of metabolic or cardiovascular disease
  • Female participants because of unknown effects of the menstrual cycle on the levels of the measured myokines.

Treatment and study plan

Reduced-Exertion High-Intensity Interval Training (REHIT)

Behavioral

Description same as Arm description.

Other names: Sprint interval training (SIT)

Primary outcomes

  1. Training induced changes in VO2max

    Time frame: Pre-intervention and 3 days post-intervention

    Maximal aerobic capacity (VO2max) will be measured pre- and post-training to determine the change in VO2max.

  2. Training induced changes in plasma myokines

    Time frame: Pre-intervention and 3 days post-intervention

    Plasma myokine levels of 8 myokines will be measured pre- and post-training to determine the change in plasma myokine levels.

Sponsors and collaborators

Lead sponsor

University of Stirling

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Nov 21, 2023
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.